Normal Ovulatory Women with Polycystic Ovaries Have Hyperandrogenic Pituitary-Ovarian Responses To Gonadotropin-Releasing Hormone-Agonist Testing*
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Women with polycystic ovary syndrome (PCOS) have chronic anovulation and hyperandrogenism and frequently have abnormalities in their lipid profiles and insulin/insulin-like growth factor axis that increase their lifetime risk for cardiovascular disease. Normal ovulatory women may have polycystic ovaries on ultrasonography and yet lack the clinical features of PCOS. To further explore whether ovulatory women without clinical/biochemical hyperandrogenism but with polycystic appearing ovaries (ov-PAO) have subclinical features of PCOS, we prospectively characterized 26 ov-PAO women and matched them by age and body mass index to 25 ovulatory women with normal appearing ovaries (ov-NAO) and to 22 women with PCOS. After an overnight fast, all women had baseline endocrine and metabolic assessments. In addition, a subset of each group of women underwent GnRH-agonist (leuprolide acetate 1 mg sc) testing, ACTH stimulation, and an insulin tolerance test (ITT). At baseline, ov-PAO and ov-NAO women had similar endocrine profiles (LH, LH:FSH, androstenedione, and DHEAS). Compared with ov-NAO, 31% of ov-PAO women had reduced glucose responses after insulin (Kitt), suggesting mild insulin resistance, and 35% had high density lipoprotein levels below 35 mg/dL, a level considered to represent significant cardiovascular risk. After GnRH-agonist, ov-PAO women had response patterns in LH, total testosterone, and 17-hydroxyprogesterone (17-OHP) that were intermediate between ov-NAO and women with PCOS. Ovarian responses were above the normal range in 30–40% of women with ov-PAO. In ov-PAO, peak responses of LH after leuprolide correlated with triglyceride levels (P < 0.05) and peak responses of 17-OHP correlated inversely with Kitt values (P < 0.05). No significant differences were noted with ACTH testing. In conclusion, occult biochemical ovarian hyperandrogenism may be uncovered using GnRH-agonist in ovulatory women with ov-PAO, while adrenal responses remain normal. Subtle metabolic abnormalities may also be prevalent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Birdsall, M. A., Farquhar, C. M., & White, H. D. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-1-199701010-00005 · Cited by 327
Cited by
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132
“In fact, although an initial report found no differences in mean androgen levels (59), other studies have found that a significant proportion of asymptomatic women with polycystic ovaries have hyperandrogenism (70, 71) and some others have found an increase of mean androgens (60, 68, 72).”
BackgroundSelf-citationDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Rosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.217 · Cited by 1,488
Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1018 · Cited by 1,020
Franks, S. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.1.89 · Cited by 806
Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis
Escobar-Morreale, H. F., Luque-Ramírez, M., & González, F. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.11.036 · Cited by 517
Developmental origin of polycystic ovary syndrome—a hypothesis
Abbott, D., Dumesic, D., & Franks, S. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1740001 · Cited by 504
“Super- imposed on this developmental process are interacting genetic and environmental factors that may alter phenotypic expression of PCOS during adult life, particularly the susceptibility to anovulation (White et al. 1995, Franks et al. 1997, Chang et al. 2000).”
BackgroundPolycystic ovary syndrome and cardiovascular disease: a premature association?
Legro, R. S. (2003) · Endocrine Reviews · doi:10.1210/er.2003-0004 · Cited by 466
Lujan, M. E., Jarrett, B. Y., Brooks, E. D., Reines, J. K., Peppin, A. K., Muhn, N., Haider, E., Pierson, R. A., & Chizen, D. R. (2013) · Human Reproduction · doi:10.1093/humrep/det062 · Cited by 459
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature
Azziz, R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2153 · Cited by 432
The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome
Escobar-Morreale, H. F., Luque-Ramírez, M., & San Millán, J. L. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0004 · Cited by 422
Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome
Stener-Victorin, E., Padmanabhan, V., Walters, K. A., Campbell, R. E., Benrick, A., Giacobini, P., Dumesic, D. A., & Abbott, D. H. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa010 · Cited by 348
Polycystic ovary syndrome: Syndrome XX?
Sam, S., & Dunaif, A. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2003.08.002 · Cited by 302
Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification
Dapas, M., & Dunaif, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac001 · Cited by 300
Silfen, M. E., Denburg, M. R., Manibo, A. M., Lobo, R. A., Jaffe, R., Ferin, M., Levine, L. S., & Oberfield, S. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030617 · Cited by 269
Self-citationPolycystic ovarian morphology in postmenarchal adolescents
Codner, E., Villarroel, C., Eyzaguirre, F. C., López, P., Merino, P. M., Pérez-Bravo, F., Iñiguez, G., & Cassorla, F. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.06.015 · Cited by 113
“Previous studies performed in adults have shown that PCOM is associated with functional ovarian hyperandrogenism, as demonstrated by higher stimulated 17OHP levels during the GnRH agonist test (27).”
ResultFunctional Significance of Polycystic-Size Ovaries in Healthy Adolescents
Mortensen, M., Rosenfield, R. L., & Littlejohn, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0835 · Cited by 103
Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome
Ahmed, M. I., Duleba, A. J., El Shahat, O., Ibrahim, M. E., & Salem, A. (2008) · Human Reproduction · doi:10.1093/humrep/den273 · Cited by 58
“Although multiple alterations in the function of these organs have been documented, it is uncertain which, if any, of these organs initiates the development of PCOS (Chang et al., 2000; Lobo and Carmina, 2000).”
Background
Metadata
- Authors
- Chang, P. L., Lindheim, S. R., Lowre, C., Ferin, M., Gonzalez, F., Berglund, L., Carmina, E., Sauer, M. V., & Lobo, R. A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-03-01
- Volume
- 85
- Issue
- 3
- Pages
- 995-1000
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2056140632
- Cited by
- 99
- References
- 1
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.